Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union

GlobeNewswire Inc. | Nov 6, 2026 8:00 AM EST

– Final European Commission decision expected during Q4 2026